> Details

Wolf, J.; Helland, Å.; Oh, I.-J.; Migliorino, M.R.; Dziadziuszko, R.; Wrona, A.; de Castro, J.; Mazieres, J.; Griesinger, F.; Chlistalla, M.; Cardona, A.; Ruf, T.; Trunzer, K.; Smoljanovic, V.; Novello, S.

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
  • Contributor: Wolf, J.; Helland, Å.; Oh, I.-J.; Migliorino, M.R.; Dziadziuszko, R.; Wrona, A.; de Castro, J.; Mazieres, J.; Griesinger, F.; Chlistalla, M.; Cardona, A.; Ruf, T.; Trunzer, K.; Smoljanovic, V.; Novello, S.
  • Published: Elsevier BV, 2022
  • Published in: ESMO Open, 7 (2022) 1, Seite 100333
  • Language: English
  • DOI: 10.1016/j.esmoop.2021.100333
  • ISSN: 2059-7029
  • Origination:
  • Footnote:
  • Access State: Open Access